Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

Recent developments in nanomedicine for melanoma treatment

Jianqin TangDepartment of Dermatology Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 ChinaXiao‐Yang HouDepartment of Dermatology Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 ChinaChun‐Sheng YangDepartment of Dermatology Affiliated Huai'an Hospital of Xuzhou Medical University Huai'an 223002 ChinaYaxi LiDepartment of Dermatology Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 ChinaYong XinDepartment of Radiotherapy Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 ChinaWenwen GuoDepartment of Radiotherapy Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 ChinaZhiping WeiDepartment of Dermatology Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 ChinaLiu Yan-qunDepartment of Dermatology Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 ChinaGuan JiangDepartment of Dermatology Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 China
2017en
ABI

Аннотация

Melanoma is a most aggressive skin cancer with limited therapeutic options and its incidence is increasing rapidly in recent years. The discovery and application of new targeted therapy agents have shown significant benefits. However, adverse side-effects and resistance to chemotherapy remain formidable challenges in the clinical treatment of malignant melanoma. Nanotherapeutics offers an important prospect of overcoming these drawbacks. The anti-tumoral applications of nanomedicine are varied, including those in chemotherapy, RNA interference, photothermal therapy, and photodynamic therapy. Furthermore, nanomedicine allows delivery of the effector structures into the tumor site via passive or active targeting, thereby allowing increased therapeutic specificity and reduced side effects. In this review, we summarize the latest developments in the application of nanocarrier-mediated targeted drug delivery to melanoma and nanomedicine-related clinical trials in melanoma treatment. We also discuss existing problems and opportunities for future developments, providing direction and new thoughts for further studies.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0